Neutralisation of the interleukin-33/ST2 pathway ameliorates experimental colitis through enhancement of mucosal healing in mice.
MouseChemical/toxinSt2-deficient and IL-33-deficient mice backcrossed eight times onto C57BL/6J, and wild-type C57BL/6Jmalen = Trinitrobenzene sulphonic acid: 6 animals per group. Dextra…Intraperitoneal for anti-ST2 antibody and recombinant IL-33; intrarectal for trinitrobenzene sulphonic acid; oral (drinking water) for dextran sodium sulphateAnti-ST2 antibody 50 µg per mouse; recombinant murine IL-33…Anti-ST2 antibody on days 1, 3, 5 and 7 after starting dextran sodium sulphate;…
Model: Experimental colitis induced by intrarectal 2,4,6-trinitrobenzene sulphonic acid (150 mg/kg) or by 3% dextran sodium sulphate in drinking water for 7 days, plus endoscopic biopsy-induced acute mechanical mucosal wounding of the descending colon
Genetic ablation of ST2 or IL-33 and treatment with a neutralising anti-ST2 antibody reduced disease activity, histological damage and colonic IL-6 and improved mucosal wound healing, whereas exogenous recombinant IL-33 worsened colitis and increased intestinal permeability.
Extraction: extract · Supplied extraction confidence: 0.9. Machine-extracted fields require source verification.